Webinars
CryostaX Pellets: Improving hepatocyte pooling, activity and lab efficiency
Presenter: Chris Bohl, Ph.D., Global Technical Support Manager Synopsis: CryostaX® hepatocytes are created using a patented process that produces unique single-donor cell pellets. This format allows for distinct benefits...
Challenges & Solutions In Today’s In Vitro Transporter Research Landscape
Recent changes to the FDA in vitro DDI guidance document have emphasized the need for more considered transporter study designs to better inform in vivo expectations for drugs in development. Additionally, challenges associated with some diverse compounds in what should have been straightforward in vitro transporter assays will be examined. Case studies will explore the problematic observations or data, creative methods of troubleshooting applied, and how we can learn from those experiences to better understand and address surprises in future transporter studies...
Patient-Derived Tumor Organoids for Personalized Medicine & Targeted Drug Discovery
Presenter: Motoki Takagi, Ph.D., Professor, Medical-industrial Translational Research Center, Fukushima Medical University Synopsis: Patient-derived tumor organoids (PDOs) are cell aggregates produced by in vitro cell...
Drug Metabolizing Enzymes and Transporters in NASH
“Drug Metabolizing Enzymes and Transporters in NASH: Research Application of Variants of Fatty Liver Disease (FLD) Tissues” Presented by Maciej Czerwinski, Ph.D., XenoTech Director of Consulting
Adverse drug interaction risks in genetically-defined subpopulations
Presenter: Maciej Czerwinski, Ph.D., Director of XenoTech Products R&D Synopsis: An increased appreciation of the effects of genetic variability on the pharmacokinetic and pharmacodynamic properties of xenobiotics creates a...
Evaluation of Ketoconazole and its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters
Presented by: Lydia Vermeer, Ph.D., Senior Scientist, Drug Transport Ketoconazole is an orally available, synthetic, broad spectrum, antifungal agent. Approved in 1982 by the FDA...
Tritosomes and Lysosomes for Characterization of Biologic Drugs
Presented by Dr. Chris Bohl, Manager of Techical Support, Products Synopsis Tritosomes and Lysosomes for Characterization of Biologic Drugs: Investigation of freshly purified rat tritosomes...
Aldehyde Oxidase: Why In Vitro Absolute Activity Doesn’t Matter
Presented by: Brian Ogilvie and Faraz Kazmi Biotransformation by aldehyde oxidase (AO) is an important clearance mechanism for many drugs and drug candidates, with increasing...
Navigating the Transporter Wave of 2013: A Review of the Seven Recent ITC Publications on Drug Transporters
Presented by: Greg Loewen, Amanda Hays and Andrea Wolff Seven papers were published by the International Transporter Consortium (ITC) in the July 2013 issue of Clinical...
Exploring the Mechanism of CYP3A4 Inactivation by Lapatinib Through In Vitro Metabolite Char.
Presented by: Joanna Barbara, Ph.D. Metabolism-dependent inhibition of cytochrome P450 enzymes has the potential to cause clinically-relevant drug-drug interactions. Alkylamine drugs are known for their propensity...
What topic would you like to hear about?
Our experts are constantly on the hunt for new and exciting topics to present on, and nothing helps us figure out what you want to hear more than requests and feedback! Use our form to submit your request so we can continue producing educational materials you look forward to
